Form 4: Astera Labs President and COO Sells Over 76,000 Shares Under Pre-Arranged Trading Plan

Astera Labs' President and COO, Sanjay Gajendra, sold 76,373 shares of common stock on June 18, 2025, through a pre-established Rule 10b5-1 trading plan.

Summary

• Sanjay Gajendra, President and COO, and a Director of Astera Labs, Inc. (ALAB), reported the sale of 76,373 shares of common stock.
• The sales occurred on June 18, 2025.
• The transactions were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Gajendra on November 30, 2024.
• The shares were sold at weighted average prices ranging from $98.1927 to $99.2065 per share.
• Specifically, 52,933 shares were sold at $98.3779, 4,926 shares at $99.2065, 9,257 shares at $98.1927, and another 9,257 shares at $98.1968.
• Following these transactions, Mr. Gajendra continues to beneficially own 2,262,318 shares directly and 7,360,545 shares indirectly through various estate planning trusts (Trust 1, Trust 2, and Trust 3).
• Mr. Gajendra disclaims beneficial ownership of the shares held by the trusts, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-established Rule 10b5-1 trading plan mitigates concerns about opportunistic selling based on non-public information. It suggests a planned diversification or liquidity event rather than a reaction to adverse company developments.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled and not based on recent, non-public information, mitigating concerns about opportunistic selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-planned nature.

Risks

• No specific risks are mentioned in the document beyond the general market perception of insider selling.

Future Outlook

NA

Management Comments

• "The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2024."
• "The Reporting Person disclaims beneficial ownership of these securities [held by trusts], except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."

Industry Context

This Form 4 filing details an insider stock transaction specific to Astera Labs, Inc. and does not provide information relevant to broader industry trends or competitive analysis. Such filings are standard disclosures for publicly traded companies regarding executive stock ownership changes.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a neutral event due to the 10b5-1 plan, or potentially a slight negative if they overlook the plan's context. The continued significant beneficial ownership by the insider may reassure some.

Key Dates

Recommendation

Keywords

Astera Labs, ALAB, Form 4, insider trading, stock sale, Rule 10b5-1 plan, executive compensation, beneficial ownership, corporate governance, technology